All In Biotech

Drug Trial Radar · NCT07304440

Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study

Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Jun 15, 2028

Study completion Jun 15, 2028

Sponsor

Lead sponsor
Adia Med of Winter Park LLCAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 12-month study tests whether AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione improves autism symptoms more than glutathione alone in children ages 3-12. About 100 children with confirmed autism will be randomly assigned to one of two groups. One group receives monthly IV AdiaVita plus IV glutathione for 3 months. The other group receives IV glutathione plus a saline placebo infusion for 2 months. Both groups also use a topical glutathione spray twice a day at home. Symptoms are tracked with the Autism Treatment Evaluation Checklist (ATEC), completed by a parent and by a therapist or teacher. Safety is monitored at clinic visits through Month 12. Children who first receive glutathione only, may crossover to receive AdiaVita at no extra cost if they stay medically stable and their family agrees. Participation is voluntary. The study fee is $12,000.

Conditions

  • Autism Spectrum Disorder
  • Autism
  • ASD
  • Autism Spectrum Disorder (ASD)

Interventions

  • Umbilical Cord Blood-Derived Stem Cells and ExosomesBiological

    Intravenous infusion of cryopreserved allogeneic umbilical cord blood-derived product containing viable mononuclear cells (including hematopoietic and mesenchymal stem/stromal cells) and exosomes.

  • GlutathioneDrug

    Reduced L-glutathione administered Intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 6Time frame: Baseline and Month 6

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Adia Med Of Winter Park

    Winter Park, Florida · Recruiting

  • The Lyday Center

    Green Bay, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.